Cargando…
Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study
OBJECTIVES: Intravenous immunoglobulin (IVIG) is commonly used to treat severe COVID-19, although the clinical outcome of such treatment remains unclear. This study evaluated the effectiveness of IVIG treatment in severe COVID-19 patients. METHODS: This retrospective multicentre study evaluated 28-d...
Autores principales: | Liu, Jiao, Chen, Yizhu, Li, Ranran, Wu, Zhixiong, Xu, Qianghong, Li, Zhongyi, Annane, Djillali, Feng, Huibin, Huang, Sisi, Guo, Jun, Zhang, Lidi, Ye, Xiaofei, Zhu, Wei, Du, Hangxiang, Liu, Yong'an, Wang, Tao, Chen, Limin, Wen, Zhenliang, Teboul, Jean-Louis, Chen, Dechang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131555/ https://www.ncbi.nlm.nih.gov/pubmed/34020032 http://dx.doi.org/10.1016/j.cmi.2021.05.012 |
Ejemplares similares
-
Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study
por: Liu, Jiao, et al.
Publicado: (2021) -
Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case–control study
por: Liu, Jiao, et al.
Publicado: (2022) -
Down‐regulation of circDMNT3B is conducive to intestinal mucosal permeability dysfunction of rats with sepsis via sponging miR‐20b‐5p
por: Liu, Jiao, et al.
Publicado: (2020) -
Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients
por: Meng, Mei, et al.
Publicado: (2021) -
Identification and validation of prognostic factors in patients with COVID-19: A retrospective study based on artificial intelligence algorithms
por: Zhang, Sheng, et al.
Publicado: (2021)